Navigation Links
Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Financial Results and Reviews Recent Developments
Date:3/11/2011

ry and metabolic diseases. Arena's most advanced drug candidate is lorcaserin, which is intended for weight management. Arena's wholly owned subsidiary, Arena Pharmaceuticals GmbH, has granted Eisai Inc. exclusive rights to market and distribute lorcaserin in the United States following FDA approval of the New Drug Application (NDA) for lorcaserin.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the advancement, therapeutic indication and use, mechanism of action, and potential of Arena's drug candidates; the potential of GPR119 and GPR119 agonists; addressing outstanding issues to the FDA's satisfaction; potential FDA approval and commercialization of lorcaserin; the Eisai collaboration and potential activities thereunder; submission of an application for European approval of lorcaserin; patent coverage; financial guidance; the reduction of Arena's workforce, including the expected size, timing, related charges and benefits; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that the impact of Arena's workforce reduction may not be as expected; the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approv
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
(Date:7/30/2014)... LAKE FOREST, Ill., July 30, 2014  Hospira, ... leading provider of injectable drugs and infusion technologies, ... June 30, 2014. Net sales for the quarter ... share were $0.72. (Adjusted* measures exclude specified items ... the attached schedules.) On a U.S. Generally Accepted ...
(Date:7/30/2014)... DIEGO , July 30, 2014   ... biotech company that designs and develops novel diagnostics ... of cancer, announced today the completion of a ... financing included new investors RusnanoMedInvest (RMI) and Arcus ... and Pfizer Venture Investments, as well as undisclosed ...
Breaking Medicine Technology:Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... announcement today, the University of California Los Angeles (UCLA) ... report the launch of the CLEAR Study , ... Obstructive Pulmonary Disease (COPD).  COPD is a leading and ... Organization, will become the world,s third most common cause ...
... 6, 2012 HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) ... results for the three and 12 months ended December ... on Thursday, February 16, 2012 (being midnight Australian Eastern ... The Company plans to release the financial results prior ...
Cached Medicine Technology:ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients 2ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients 3ERT and UCLA Initiate Innovative Pilot Program for Chronically Ill Patients 4HeartWare Schedules Fourth Quarter Conference Call and Webcast 2
(Date:7/31/2014)... 1Heart Business Academy conducts ‘Continuing ... Belina Calderon’s group of companies engaged in Senior ... Caregiver Services, L.A. Jobs Employment Agency and Summit ... recent resource speaker and trainer Los Angeles Area ... his expertise and knowledge in best business practices ...
(Date:7/31/2014)... Chicago, IL (PRWEB) July 31, 2014 ... Brickner; “no, not the summer’s hottest metal bands ~ ... Homeostatic Cannabinoid Science ~ Publius’ July Roundup, new ... articles are noted on homeostasis and the cannabinoid system ... modulation of our health and wellness: three directly on ...
(Date:7/31/2014)... National non-profit World T.E.A.M. Sports’ annual ... September 12-14, following two years in the high Colorado ... disabled and able-bodied athletes competing together in an inclusive ... by experienced adventure athletes. , Hosted at the rustic ... Colorado River in the rugged Gore Mountains northwest of ...
(Date:7/31/2014)... In its latest blog post, Best Drug Rehabilitation , ... by during a stay in rehab can make a big ... looking at 10 tips to help drug or alcohol addicts ... lifelong process, and one that former addicts and those who ... Best Drug Rehabilitation’s CEO Per Wickstrom . , ...
(Date:7/31/2014)... When guests shop CVS, they’ll find many ... Shea Moisture. And now CVS is adding another acclaimed brand ... 1, guests will find G Natural products in CVS stores ... CEO Roger Gore was inspired to start G’Natural Herbal Products ... developing a receding hairline; he tried many products on the ...
Breaking Medicine News(10 mins):Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 2Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 3Health News:1Heart Business Academy Applauds Resource Speaker and Trainer Los Angeles Area Chamber of Commerce Ambassador Glenn Bowie 4Health News:Homeostatic Cannabinoid Science ~ Publius’ July Roundup on the Bryan William Brickner Blog 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 2Health News:World T.E.A.M. Sports’ Adventure Team Challenge Returns to Colorado’s High Country 3Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2
... Blacks 45 percent more likely to die from the disease ... News) -- Despite major progress reducing overall colorectal cancer incidence ... women are still 45 percent more likely than whites to ... a report released Monday by the American Cancer Society. , ...
... of Oregon lab have shed more light on the ... in which a methyl group is attached to DNA, ... , DNA methylation is essential for normal growth and ... in long-term memory, and irregularities in its process are ...
... The Cardiopulmonary Research Science,and Technology Institute (CRSTI), ... for a Phase 2 clinical trial for ... of,Gene Therapy in Cardiac Disease" (CUPID Trial) ... at the American Heart Association Scientific,Sessions 2008. ...
... food costs, many,families are economizing on groceries but one thing ... cents per 8-ounce glass, on a gallon basis, milk,offers more ... the,supermarket -- proving key vitamins and minerals like calcium and ... moms don,t cut milk from,their grocery lists, the National got ...
... CORPUS CHRISTI, Texas, Dec. 15 With rising food costs,many ... not cut,back on is nutrition. At about 25 cents per ... penny than almost any other beverage option in,the supermarket -- ... are important for the entire family. To ensure moms don,t ...
... Dec. 15 With rising food costs, many,families are ... cut back,on is nutrition. At about 25 cents per ... per penny than almost any other beverage option in ... and vitamin D,that are important for the entire family. ...
Cached Medicine News:Health News:Colorectal Cancer Racial Gap Still Growing 2Health News:Work with fungus uncovering keys to DNA methylation 2Health News:CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure 2Health News:CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure 3Health News:CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure 4Health News:Milk is One Beverage Kansas City Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Kansas City Can't Afford to Keep Off the Grocery List 3Health News:Milk is One Beverage Corpus Christi Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Corpus Christi Can't Afford to Keep Off the Grocery List 3Health News:Milk is One Beverage Birmingham Can't Afford to Keep Off the Grocery List 2Health News:Milk is One Beverage Birmingham Can't Afford to Keep Off the Grocery List 3
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
... Posterior segment surgeries Vitrectomy-Lensectomy + Irrigation/Aspiration ... Peristaltic Linear Aspiration. Interchangeable disposable blades ... action. Easy to read LED display ... from 1- 600 cuts per minute. ...
...
Enables Delicate Lifting Of The Flap Without Causing Trauma - Also available in Titanium...
Medicine Products: